|
Valoración de DCF de China Pharma Holdings, Inc. (CPHI)
CN | Healthcare | Drug Manufacturers - Specialty & Generic | AMEX
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
China Pharma Holdings, Inc. (CPHI) Bundle
Como inversor o analista, la calculadora DCF (CPHI) es su recurso de referencia para una valoración precisa. Con datos reales de China Pharma Holdings, Inc., puede ajustar fácilmente los pronósticos y observar los efectos en tiempo real.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.9 | 10.9 | 9.6 | 8.1 | 7.0 | 6.3 | 5.6 | 5.1 | 4.5 | 4.1 |
| Revenue Growth, % | 0 | -0.52625 | -11.27 | -15.95 | -13.48 | -10.31 | -10.31 | -10.31 | -10.31 | -10.31 |
| EBITDA | -17.5 | .1 | .2 | -.8 | .0 | -1.3 | -1.2 | -1.1 | -1.0 | -.9 |
| EBITDA, % | -159.75 | 0.98332 | 2.39 | -10.34 | 0.12032 | -21.37 | -21.37 | -21.37 | -21.37 | -21.37 |
| Depreciation | 2.9 | 2.7 | 3.1 | 2.7 | 2.8 | 2.0 | 1.8 | 1.6 | 1.4 | 1.3 |
| Depreciation, % | 26.81 | 24.66 | 32.02 | 33.32 | 39.27 | 31.22 | 31.22 | 31.22 | 31.22 | 31.22 |
| EBIT | -20.4 | -2.6 | -2.9 | -3.5 | -2.7 | -3.0 | -2.7 | -2.4 | -2.1 | -1.9 |
| EBIT, % | -186.57 | -23.67 | -29.64 | -43.66 | -39.15 | -47.22 | -47.22 | -47.22 | -47.22 | -47.22 |
| Total Cash | 1.1 | 1.0 | 4.9 | 2.0 | 1.4 | 1.4 | 1.3 | 1.2 | 1.0 | .9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .7 | .6 | .8 | .5 | .7 | .4 | .4 | .4 | .3 | .3 |
| Account Receivables, % | 6.24 | 5.37 | 8.66 | 5.73 | 9.45 | 7.09 | 7.09 | 7.09 | 7.09 | 7.09 |
| Inventories | 3.6 | 3.7 | 3.3 | 2.9 | 3.7 | 2.4 | 2.2 | 1.9 | 1.7 | 1.6 |
| Inventories, % | 32.85 | 34.1 | 34.64 | 36.37 | 53.24 | 38.24 | 38.24 | 38.24 | 38.24 | 38.24 |
| Accounts Payable | 1.4 | 1.2 | .9 | .7 | 1.0 | .7 | .6 | .6 | .5 | .5 |
| Accounts Payable, % | 12.51 | 11.36 | 9.61 | 8.23 | 13.78 | 11.1 | 11.1 | 11.1 | 11.1 | 11.1 |
| Capital Expenditure | -.1 | -.9 | -.4 | -.4 | .0 | -.2 | -.2 | -.2 | -.2 | -.2 |
| Capital Expenditure, % | -1.24 | -7.98 | -4.54 | -4.96 | -0.16426 | -3.78 | -3.78 | -3.78 | -3.78 | -3.78 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -20.7 | -2.8 | -3.3 | -9.1 | -2.7 | -3.0 | -2.7 | -2.4 | -2.1 | -1.9 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -20.8 | -1.2 | -.9 | -6.3 | -.7 | .0 | -.9 | -.8 | -.7 | -.6 |
| WACC, % | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1 | |||||||||
| Terminal Value | -13 | |||||||||
| Present Terminal Value | -9 | |||||||||
| Enterprise Value | -11 | |||||||||
| Net Debt | 3 | |||||||||
| Equity Value | -15 | |||||||||
| Diluted Shares Outstanding, MM | 3 | |||||||||
| Equity Value Per Share | -4.29 |
What You Will Get
- Real CPHI Data: Preloaded financials – encompassing revenue to EBIT – based on actual and projected figures.
- Full Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to evaluate the effects of changes on CPHI’s fair value.
- Versatile Excel Template: Designed for quick edits, scenario analysis, and comprehensive projections.
- Time-Saving and Accurate: Bypass the hassle of building models from scratch while ensuring precision and adaptability.
Key Features
- 🔍 Real-Life CPHI Financials: Pre-filled historical and projected data for China Pharma Holdings, Inc. (CPHI).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate CPHI’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize CPHI’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download the Template: Gain immediate access to the Excel-based CPHI DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional factors.
- Instant Calculations: The model automatically recalculates the intrinsic value of China Pharma Holdings, Inc. (CPHI).
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Leverage the results to inform your investment or financial analysis decisions.
Why Choose This Calculator for China Pharma Holdings, Inc. (CPHI)?
- Accurate Data: Up-to-date financial information for CPHI ensures trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants focused on CPHI.
- User-Friendly: Simple interface and guided instructions make it accessible for all users.
Who Should Use This Product?
- Investors: Evaluate China Pharma Holdings, Inc.'s (CPHI) market position before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and analyze financial forecasts for CPHI.
- Startup Founders: Understand the valuation strategies of established companies like China Pharma Holdings, Inc. (CPHI).
- Consultants: Create detailed valuation assessments and reports for clients focusing on CPHI.
- Students and Educators: Utilize real-time data from China Pharma Holdings, Inc. (CPHI) to enhance learning on valuation practices.
What the Template Contains
- Pre-Filled DCF Model: China Pharma Holdings, Inc.’s (CPHI) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate China Pharma Holdings, Inc.’s (CPHI) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.